Derazantinib

small molecule

Identifier: CI-DRUG-00000185
Entity page: /drug/derazantinib ↗
Edges: 17

Neighbours: 6 cancers4 genes2 variants4 trials
Drawn: 16 of 16 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Derazantinib predicts response to …PREDICTS_RESPONSE_TO2 of 2
← predicts response to	FGFR2 Fusionfusion	sensitivity	B	Intrahepatic Cholangiocarcinoma	1	Curated	civic	graph →
← predicts response to	FGFR2 Fusionfusion	sensitivity	B

Derazantinib targets …TARGETS4 of 4
→ targets	FGFR2	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	FGFR1	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	FGFR4	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	FGFR3	—	INHIBITOR	—	1	Curated	chembl	graph →

Derazantinib investigated for …INVESTIGATED_FOR5 of 5
→ investigated for	Intrahepatic Cholangiocarcinomasubtype	supports	B	Intrahepatic Cholangiocarcinoma	1	Curated	civic	graph →
→ investigated for	Cholangiocarcinomasubtype	unknown	2	Cholangiocarcinoma	1	Curated	chembl	graph →
→ investigated for	Gastric Neoplasmcancer_family	unknown	1	Gastric Neoplasm	1	Curated	chembl	graph →
→ investigated for	Bladder Neoplasmsubtype	unknown	1	Bladder Neoplasm	1	Curated	chembl	graph →
→ investigated for	Neoplasmcancer_family	unknown	1	Neoplasm	1	Curated	chembl	graph →

Derazantinib investigated in trials for …INVESTIGATED_IN_TRIALSderived2 of 2
→ investigated in trials for	Intrahepatic Cholangiocarcinomasubtype 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Intrahepatic Cholangiocarcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Gastric Adenocarcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Gastric Adenocarcinoma	1	Observed	clinicaltrials	graph →

Derazantinib studied in …STUDIED_INderived4 of 4
→ studied in	NCT05174650Phase 2 · active not recruiting Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements · 4 trials list this drug (1 active)	—	—	Intrahepatic Cholangiocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04087876no longer available Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations · 4 trials list this drug (1 active)	—	—	Intrahepatic Cholangiocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04604132Phase 1/Phase 2 · terminated Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma · 4 trials list this drug (1 active)	—	—	Gastric Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03230318Phase 2 · completed Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma · 4 trials list this drug (1 active)	—	—	Intrahepatic Cholangiocarcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths